Golimumab, SCH 900259, MK-8259, CNTO-148: A Comparative Review

This assessment reviews four separate biological agents : golimumab, SCH 900259, MK-8259, and CNTO-148. Golimumab, a recognized antibody targeting TNF-alpha, functions as a standard against which the experimental compounds—S

Vantictumab, formerly labeled as OMP18R5, represents an novel monoclonal agent designed to specifically target bone associated protein 18R5. Such treatment is actively evaluated by researchers in potential treatments in several orthopedic disorders, particularly conditions involving abnormal bone